$833 Million is the total value of Rhenman & Partners Asset Management AB's 96 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 51.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | iShares Tr Nasdaq Biotech ETFput | $73,794,000 | – | 200,000 | +100.0% | 8.86% | – | |
| New | Select Sector SPDR Tr SBI Healthcareput | $52,073,000 | – | 700,000 | +100.0% | 6.25% | – | |
| UNH | Buy | United Health Group Inc | $28,182,000 | +83.3% | 231,000 | +77.7% | 3.38% | +30.5% |
| ALXN | Buy | Alexion Pharmaceuticals Inc | $24,006,000 | +20.5% | 132,800 | +15.5% | 2.88% | -14.2% |
| ALKS | Buy | Alkermes Plc | $22,455,000 | +42.8% | 349,000 | +35.3% | 2.70% | +1.7% |
| BIIB | Buy | Biogen Inc | $20,315,000 | +18.2% | 50,291 | +23.6% | 2.44% | -15.8% |
| CVS | Buy | CVS Health Corp | $19,298,000 | +29.0% | 184,000 | +26.9% | 2.32% | -8.1% |
| JNJ | New | Johnson & Johnson | $18,615,000 | – | 191,000 | +100.0% | 2.24% | – |
| CAH | Buy | Cardinal Health Inc | $17,985,000 | +40.9% | 215,000 | +52.1% | 2.16% | +0.4% |
| ABBV | Buy | AbbVie Inc | $15,655,000 | +21.6% | 233,000 | +5.9% | 1.88% | -13.4% |
| RAD | Buy | Rite Aid Corp | $15,172,000 | +36.8% | 1,817,000 | +42.3% | 1.82% | -2.6% |
| LLY | Buy | Eli Lilly & Co | $14,611,000 | +55.9% | 175,000 | +35.7% | 1.76% | +11.1% |
| BMY | Buy | Bristol Myers Squibb Co | $13,175,000 | +58.3% | 198,000 | +53.5% | 1.58% | +12.8% |
| AGN | New | Allergan Plc | $12,745,000 | – | 42,000 | +100.0% | 1.53% | – |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $12,584,000 | +34.6% | 92,000 | +22.7% | 1.51% | -4.1% |
| JAZZ | Buy | Jazz Pharmaceuticals Plc | $12,325,000 | +29.7% | 70,000 | +27.3% | 1.48% | -7.6% |
| MDT | New | Medtronic Plc | $11,471,000 | – | 154,800 | +100.0% | 1.38% | – |
| CEMP | Buy | Cempra Inc | $9,523,000 | +49.8% | 277,161 | +49.6% | 1.14% | +6.7% |
| ANTM | New | Anthem Inc | $9,520,000 | – | 58,000 | +100.0% | 1.14% | – |
| PRGO | Buy | Perrigo Co Plc | $8,687,000 | +162.4% | 47,000 | +135.0% | 1.04% | +86.9% |
| BDX | New | Becton Dickinson & Co | $8,499,000 | – | 60,000 | +100.0% | 1.02% | – |
| LH | Buy | Laboratory Corp of America Hgs | $8,485,000 | +72.5% | 70,000 | +79.5% | 1.02% | +22.9% |
| ACAD | Buy | Acadia Pharmaceuticals Inc | $7,999,000 | +43.5% | 191,000 | +11.7% | 0.96% | +2.2% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $7,360,000 | +33.0% | 61,400 | +15.8% | 0.88% | -5.3% |
| DXCM | Buy | Dexcom Inc | $7,358,000 | +53.3% | 92,000 | +19.5% | 0.88% | +9.3% |
| COO | New | Cooper Companies Inc (The) | $7,297,000 | – | 41,000 | +100.0% | 0.88% | – |
| ESRX | New | Express Scripts Hg Co | $7,026,000 | – | 79,000 | +100.0% | 0.84% | – |
| ABMD | Buy | Abiomed Inc | $6,836,000 | +73.6% | 104,000 | +89.1% | 0.82% | +23.6% |
| ITCI | Buy | Intra-Cellular Therapies Inc | $6,582,000 | +50.6% | 206,000 | +12.6% | 0.79% | +7.2% |
| AET | Buy | Aetna Inc | $6,500,000 | +48.8% | 51,000 | +24.4% | 0.78% | +6.0% |
| STJ | Buy | St Jude Medical Inc | $6,065,000 | +90.0% | 83,000 | +70.1% | 0.73% | +35.3% |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $5,793,000 | -10.7% | 24,000 | +4.3% | 0.70% | -36.4% |
| CERN | Buy | Cerner Corp | $5,732,000 | +18.6% | 83,000 | +25.8% | 0.69% | -15.6% |
| MYL | New | Mylan N.V. | $5,632,000 | – | 83,000 | +100.0% | 0.68% | – |
| TEVA | Buy | Teva Pharma Ind Ltd ADR repr 1 Shareadr | $5,437,000 | +74.5% | 92,000 | +84.0% | 0.65% | +24.4% |
| CLVS | Buy | Clovis Oncology Inc | $5,340,000 | +33.2% | 60,765 | +12.5% | 0.64% | -5.2% |
| KERX | Buy | Keryx Biopharmaceuticals Inc | $5,329,000 | +40.9% | 534,000 | +79.8% | 0.64% | +0.3% |
| LBIO | New | Lion Biotechnologies Inc | $5,099,000 | – | 556,000 | +100.0% | 0.61% | – |
| CLDX | Buy | Celldex Therapeutics Inc | $4,968,000 | +49.8% | 197,000 | +65.5% | 0.60% | +6.8% |
| THOR | Buy | Thoratec Corp | $4,903,000 | +34.5% | 110,000 | +26.4% | 0.59% | -4.1% |
| TMO | New | Thermo Fisher Scientific Inc | $4,801,000 | – | 37,000 | +100.0% | 0.58% | – |
| ENDP | Buy | Endo International Plc | $4,697,000 | +95.8% | 58,976 | +120.5% | 0.56% | +39.3% |
| ABC | Buy | AmerisourceBergen Corp | $4,466,000 | +3.4% | 42,000 | +10.5% | 0.54% | -26.4% |
| CNC | Buy | Centene Corp | $4,342,000 | +28.0% | 54,000 | +12.5% | 0.52% | -8.9% |
| MGNX | Buy | Macrogenics Inc | $4,099,000 | +23.3% | 107,959 | +1.8% | 0.49% | -12.3% |
| KITE | Buy | Kite Pharma Inc | $4,024,000 | +55.0% | 66,000 | +46.7% | 0.48% | +10.3% |
| EW | Buy | Edwards Lifesciences Corp | $3,988,000 | +47.3% | 28,000 | +47.4% | 0.48% | +5.0% |
| HALO | New | Halozyme Therapeutics Inc | $3,884,000 | – | 172,000 | +100.0% | 0.47% | – |
| ZLTQ | New | ZELTIQ Aesthetics Inc | $3,802,000 | – | 129,000 | +100.0% | 0.46% | – |
| ARIA | Buy | Ariad Pharmaceuticals Inc | $3,722,000 | +16.7% | 450,000 | +16.3% | 0.45% | -16.9% |
| PTLA | New | Portola Pharmaceuticals Inc | $3,462,000 | – | 76,000 | +100.0% | 0.42% | – |
| CATB | New | Catabasis Pharmaceuticals Inc | $3,241,000 | – | 265,427 | +100.0% | 0.39% | – |
| EPZM | New | Epizyme Inc | $3,163,000 | – | 131,785 | +100.0% | 0.38% | – |
| CMRX | Buy | Chimerix Inc | $3,049,000 | +469.9% | 66,000 | +364.8% | 0.37% | +306.7% |
| DVAX | New | Dynavax Technologies Corp | $2,877,000 | – | 122,835 | +100.0% | 0.35% | – |
| AAVL | Buy | Avalanche Biotechnologies Inc | $2,501,000 | +43.6% | 154,006 | +258.2% | 0.30% | +2.0% |
| MRTX | Buy | Mirati Therapeutics Inc | $1,574,000 | +18.3% | 50,000 | +10.2% | 0.19% | -15.6% |
| LXRX | New | Lexicon Pharmaceuticals Inc | $1,376,000 | – | 170,915 | +100.0% | 0.16% | – |
| HTWR | New | Heartware Intl Inc | $1,141,000 | – | 15,700 | +100.0% | 0.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-07-30
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.